Logo image of 1BIIB.MI

BIOGEN INC (1BIIB.MI) Stock Price, Quote, News and Overview

BIT:1BIIB - Euronext Milan - US09062X1037 - Common Stock - Currency: EUR

109.55  +1.55 (+1.44%)

1BIIB.MI Quote, Performance and Key Statistics

BIOGEN INC

BIT:1BIIB (5/13/2025, 7:00:00 PM)

109.55

+1.55 (+1.44%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap16.05B
Shares146.53M
Float146.20M
Yearly DividendN/A
Dividend YieldN/A
PE7.52
Fwd PE7.7
Earnings (Next)07-30 2025-07-30/bmo
IPO09-17 1991-09-17


1BIIB.MI short term performance overview.The bars show the price performance of 1BIIB.MI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

1BIIB.MI long term performance overview.The bars show the price performance of 1BIIB.MI in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of 1BIIB.MI is 109.55 EUR.

BIOGEN INC / 1BIIB Daily stock chart

1BIIB.MI Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 17.75 284.74B
AMG.DE AMGEN INC 13.04 128.75B
GIS.DE GILEAD SCIENCES INC 13.71 116.78B
1GILD.MI GILEAD SCIENCES INC 13.52 115.05B
VX1.DE VERTEX PHARMACEUTICALS INC N/A 98.47B
ARGX.BR ARGENX SE 108.79 31.42B
22UA.DE BIONTECH SE-ADR N/A 20.65B
IDP.DE BIOGEN INC 7.87 16.14B
1MRNA.MI MODERNA INC N/A 8.79B
0QF.DE MODERNA INC N/A 8.78B
BIO.DE BIOTEST AG 66.15 1.70B
GLPG.AS GALAPAGOS NV N/A 1.68B

About 1BIIB.MI

Company Profile

1BIIB logo image Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Company Info

BIOGEN INC

225 Binney Street

Cambridge MASSACHUSETTS US

Employees: 7605

1BIIB Company Website

1BIIB Investor Relations

Phone: 17814642000

BIOGEN INC / 1BIIB.MI FAQ

What is the stock price of BIOGEN INC today?

The current stock price of 1BIIB.MI is 109.55 EUR. The price increased by 1.44% in the last trading session.


What is the ticker symbol for BIOGEN INC stock?

The exchange symbol of BIOGEN INC is 1BIIB and it is listed on the Euronext Milan exchange.


On which exchange is 1BIIB.MI stock listed?

1BIIB.MI stock is listed on the Euronext Milan exchange.


What is the price forecast or stock price prediction for BIOGEN INC stock?

43 analysts have analysed 1BIIB.MI and the average price target is 155.91 EUR. This implies a price increase of 42.32% is expected in the next year compared to the current price of 109.55. Check the BIOGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BIOGEN INC worth?

BIOGEN INC (1BIIB.MI) has a market capitalization of 16.05B EUR. This makes 1BIIB.MI a Large Cap stock.


How many employees does BIOGEN INC have?

BIOGEN INC (1BIIB.MI) currently has 7605 employees.


Is BIOGEN INC (1BIIB.MI) expected to grow?

The Revenue of BIOGEN INC (1BIIB.MI) is expected to decline by -4.32% in the next year. Check the estimates tab for more information on the 1BIIB.MI EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BIOGEN INC (1BIIB.MI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BIOGEN INC (1BIIB.MI) stock pay dividends?

1BIIB.MI does not pay a dividend.


When does BIOGEN INC (1BIIB.MI) report earnings?

BIOGEN INC (1BIIB.MI) will report earnings on 2025-07-30, before the market open.


What is the Price/Earnings (PE) ratio of BIOGEN INC (1BIIB.MI)?

The PE ratio for BIOGEN INC (1BIIB.MI) is 7.52. This is based on the reported non-GAAP earnings per share of 14.56 and the current share price of 109.55 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 1BIIB.MI.


1BIIB.MI Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to 1BIIB.MI.


Chartmill TA Rating
Chartmill Setup Rating

1BIIB.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to 1BIIB.MI. 1BIIB.MI scores excellent on profitability, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

1BIIB.MI Financial Highlights

Over the last trailing twelve months 1BIIB.MI reported a non-GAAP Earnings per Share(EPS) of 14.56. The EPS increased by 9.22% compared to the year before.


Industry RankSector Rank
PM (TTM) 16.87%
ROA 5.82%
ROE 9.76%
Debt/Equity 0.27
Chartmill High Growth Momentum
EPS Q2Q%4.24%
Sales Q2Q%2.87%
EPS 1Y (TTM)9.22%
Revenue 1Y (TTM)-1.62%

1BIIB.MI Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 73% to 1BIIB.MI. The Buy consensus is the average rating of analysts ratings from 43 analysts.

For the next year, analysts expect an EPS growth of -2.34% and a revenue growth -4.32% for 1BIIB.MI


Ownership
Inst Owners94.24%
Ins Owners0.12%
Short Float %N/A
Short RatioN/A
Analysts
Analysts72.56
Price Target155.91 (42.32%)
EPS Next Y-2.34%
Revenue Next Year-4.32%